In Chemistry – A European Journal, we show that FibrilPaint peptides can be adapted for both detection and targeted degradation of amyloid fibrils, while retaining their binding to Tau and Huntingtin fibrils.
Our founder and CEO, Fraçoise Dekker, has been admitted to the NWO Faculty of Impact programme. Read more about the fellowship programme here.
The FibrilRuler test uses FibrilPaint to measure the length of amyloid fibrils. Promising results for this approach have been published in PNAS. For a shorter, accessible overview, see the Utrecht University news article.
His Royal Highness Prince Constantijn visited NeuroTidal Dx to learn more about our biotech start-up. Picture taken by Par-Pa photography
NeuroTidal Dx is selected to participate in BioTech Booster! The next two years, we'll work together to change the diagnostics landscape of Parkinson's.
We’re honored to have received the Jury Prize at the Challenge & Congress (June 2025), organized by the Sustainable Healthcare Challenge (SHC) at Triodos Bank. The teams were evaluated on clinical impact, potential for real-world implementation, and overall strength of the concept.
We have been awarded a NWO TakeOff Grant! Takeoff is meant to support valuable research innovations on their way to market. With this grant, we will determine clinical parameters crucial for the implementation of our detection tool.
We are participating in the Venture Challenge! This programme is known as the best in life sciences therapeutics, diagnostics and medical devices, and we are proud to be one of the teams selected for 2024.
We have succesfully graduated the Life Science Validation Program of start-up incubator UtrechtInc.
Our science is based on 25 years of expertise in protein chemistry of disease.